share_log

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

Baolingbao BiologyLtd (SZSE:002286) Strong Profits May Be Masking Some Underlying Issues

寶靈寶生物股份有限公司(SZSE:002286)強勁利潤可能掩蓋了一些潛在問題
Simply Wall St ·  11/06 00:04

Baolingbao Biology Co.,Ltd.'s (SZSE:002286) robust recent earnings didn't do much to move the stock. We think this is due to investors looking beyond the statutory profits and being concerned with what they see.

保齡寶生物股份有限公司(SZSE:002286)最近強勁的收益並沒有對股價產生太大的影響。我們認爲這是因爲投資者在關注除法定利潤外的內容時感到擔憂。

big
SZSE:002286 Earnings and Revenue History November 5th 2024
SZSE:002286 每股收益和營業收入歷史數據 2024年11月5日

How Do Unusual Items Influence Profit?

非常規項目如何影響利潤?

Importantly, our data indicates that Baolingbao BiologyLtd's profit received a boost of CN¥28m in unusual items, over the last year. While it's always nice to have higher profit, a large contribution from unusual items sometimes dampens our enthusiasm. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Baolingbao BiologyLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.

重要的是,我們的數據顯示,保齡寶生物有限公司的利潤在過去一年中因飛凡項目獲得了2800萬人民幣的提振。雖然獲得更高的利潤總是令人高興的,但飛凡項目的大幅貢獻有時會降低我們的熱情。當我們分析全球絕大多數上市公司時,我們發現重大的飛凡項目通常不會重複。這也是預料之中的,因爲這些增長被描述爲「飛凡」。如果保齡寶生物公司無法再次獲得這種貢獻,那麼其他條件不變,我們預計其利潤在當前年度將會下降。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Baolingbao BiologyLtd.

注意:我們始終建議投資者檢查資產負債表的實力。請點擊此處查看我們對保齡寶生物公司資產負債表分析。

Our Take On Baolingbao BiologyLtd's Profit Performance

我們對保齡寶生物公司的利潤表現看法

We'd posit that Baolingbao BiologyLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Baolingbao BiologyLtd's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 40% EPS growth in the last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 2 warning signs for Baolingbao BiologyLtd and you'll want to know about these bad boys.

我們認爲,由於存在較大的飛凡項目,保齡寶生物有限公司的紅利並不是對持續生產力的清晰體現。因此,我們認爲保齡寶生物有限公司的紅利利潤可能比其潛在盈利能力更好。但至少持有者可以從過去一年40%的每股收益增長中獲得一些安慰。當然,在分析其收益時我們只是觸及到了表面;人們也可以考慮利潤率、預測增長和投資回報率等其他因素。需要注意的是,在分析股票時,值得注意所涉及的風險。您可能會感興趣,我們發現了2個關於保齡寶生物有限公司的警告信號,您可能想要了解這些信息。

This note has only looked at a single factor that sheds light on the nature of Baolingbao BiologyLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這份報告僅研究了一個能揭示保齡寶生物有限公司利潤性質的因素。但如果您能集中注意力於細枝末節,總有更多發現。有些人認爲股本回報率高是優質企業的一個良好跡象。因此,您可能希望查看這裏企業的股本回報率高的免費集合,或者這份股東持股高的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論